Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematological disorders, cancer and rare immune diseases.

Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting

View Press Release View All

May 31, 2023 • 8:05am EDT

Rigel to Present at the Jefferies 2023 Global Healthcare Conference

May 2, 2023 • 4:01pm EDT

Rigel Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 25, 2023 • 8:05am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update

May 2023

View Presentation

2023 American Society of Clinical Oncology (ASCO) Annual Meeting

View Event Add to Calendar View All

Q1 2023

Quarter Ended Mar 31, 2023

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
611 Gateway Blvd
Suite 900
South San Francisco, CA 94080